

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Scheller, D. *et al.*
Serial No.: **10/565,713**
Filed: January 25, 2006
Title: SUBSTITUTED 2-AMINOTETRALIN FOR THE TREATMENT OF DEPRESSION
Group Art Unit: 1617
Examiner: U. Ramachandran
Confirmation No.: 7929
Docket No.: **6102-000008/US/NP**
Client Ref.: P/Sche/II/5/03

SUBMITTED ELECTRONICALLY VIA EFS-WEB

January 7, 2009

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

RESPONSE TO OFFICE ACTION DATED DECEMBER 10, 2008

This paper is responsive to the Office Action dated December 10, 2008 in the above referenced application, in which a shortened statutory period of one month was set for reply. This response is timely and no fee for extension of time is believed payable. If any fee should be found payable in respect of this submission, authorization is hereby provided to charge the amount of such fee to Deposit Account No. 08-0750.

1. Restriction requirement

By the present Action, Applicant is required under 35 U.S.C. §121 and §372 to restrict the application to one of the following groups:

- I. Claims 16, 36 and 68–77: therapeutic combination claims;
- II. Claims 17–28, 30–35, 37–57, 66 and 67: method claims including administering a 2-aminotetralin and (Claims 35, 56, 57, 66 and 67 only) an antidepressant; note that Claim 36 is erroneously included in Group II according to the Action);